# Product Data Sheet

Product Name: JZY3032
Cat. No.: GC81357

## Chemical Properties

Cas. No.

| | | | |
|---|---|---|---|
| Formula | $C_{52}H_{62}ClF_2N_{13}O_2$ | M.Wt | 974.58 |
| Solubility | DMSO: 100 mg/mL (102.61 mM; Need ultrasonic) | Storage | -20°C, protect from light, stored under argon |
| General tips | For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. | | |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request. | | |

Structure



## Background

JYZ3032 is an orally active super inhibitor of androgen receptor ( AR ) and p300/CBP. JYZ3032 redirects the catalytic activity of p300 and locks the complex in a transcriptionally inactive state, thereby inhibiting AR -driven transcription and proliferation. JYZ3032 induces deep and durable tumor

regression in castration-resistant and patient-derived xenograft models, and exhibits good tolerability. JYZ3032 can be used in research related to metastatic castration-resistant prostate cancer and prostate cancer [1].

In Vivo, JYZ3032 (30 mg/kg; i.p.) induces tumor regression in 75% of castrated male NSG mice bearing VCaP castration-resistant prostate cancer xenografts[1]. YZ3032 (60 mg/kg; p.o.) also achieves significant tumor inhibition with good tolerance[1]. JYZ3032 induces complete tumor regression and 100% survival for at least 35 days in NSG mice bearing patient-derived prostate cancer xenografts of MDA-PCa-183, significantly inhibits tumor growth in the MDA-PCa-146-12 model, and exhibits good tolerance[1].

In Vitro, JYZ3032 (1.0 nM; 120 h) potently inhibits the growth of 22Rv1 prostate cancer cells with an $IC_{50}$ of 1.0 nM and 69% maximum growth inhibition [1]. JYZ3032 (100 nM, Serial dilutions; 4 h pulse treatment, total 120 h) exhibits durable, sustained growth inhibitory activity in VCaP and LNCaP prostate cancer cells, with a 4-hour pulse treatment yielding comparable efficacy to continuous exposure[1]. JYZ3032 potently suppresses enhancer-associated histone acetylation marks in VCaP prostate cancer cells but not in AR-negative Kelly neuroblastoma cells, demonstrating lineage selectivity[1].

References:
[1]. Luo J, et al. Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate Cancer[J]. bioRxiv, 2026: 2026.04. 24.720638.